Cowen Remains Bullish on Galapagos NV (GLPG) After AbbVie (ABBV) Declined to Opt-In for Phase III Development of Filgotinib

Credit Suisse Downgrades Galapagos NV (GLPG) to Neutral

Credit Suisse downgraded Galapagos NV (NASDAQ: GLPG) from Outperform to Neutral and cuts its price target from EUR62 to EUR46.

Analyst V. Divan commented, "BBV's decision to opt-out of filgotinib and advance ABT-494 into phase 3 can potentially be... More

Unusual 11 Mid-Day Movers 9/25: (BLPH) (ANFI) (JBL) Higher; (EMES) (PETX) (GLPG) Lower

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 95.7% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's Phase 3 PAH program for INOpulse, which will... More

Unusual 11 Mid-Day Movers 9/25: (BLPH) (ANFI) (JBL) Higher; (EMES) (PETX) (GLPG) Lower

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 95.7% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's Phase 3 PAH program for INOpulse, which will... More

Galapagos NV (GLPG) to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis

Galapagos NV (NASDAQ: GLPG) announced today that the Company will be moving filgotinib, its highly selective JAK1 inhibitor, into Phase 3 in rheumatoid arthritis by early 2016. Filgotinib has shown best-in-class efficacy and safety in the DARWIN Phase 2B studies in rheumatoid arthritis and is now fully owned... More

Galapagos NV (GLPG) to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis

Galapagos NV (NASDAQ: GLPG) announced today that the Company will be moving filgotinib, its highly selective JAK1 inhibitor, into Phase 3 in rheumatoid arthritis by early 2016. Filgotinib has shown best-in-class efficacy and safety in the DARWIN Phase 2B studies in rheumatoid arthritis and is now fully owned... More

AbbVie (ABBV) Announces ABT-494 Meets Primary Endpoint in Two Phase 2 Trials

AbbVie (NYSE: ABBV) announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors. The clinical trials, BALANCE-I and BALANCE-II, achieved ACR20 at week 12 across all dose levels, except the... More

UPDATE: AbbVie (ABBV) to Advance ABT-494, Will Not Exercise Rights to Galapagos' (GLPG) Filgotinib

(Updated - September 25, 2015 7:25 AM EDT)

(Update included ticker for GLPG)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough... More

UPDATE: AbbVie (ABBV) to Advance ABT-494, Will Not Exercise Rights to Galapagos' (GLPG) Filgotinib

(Updated - September 25, 2015 7:25 AM EDT)

(Update included ticker for GLPG)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough... More